Navigation Links
Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
Date:5/17/2009

consistent with previous studies, the most frequently reported side effects were gastrointestinal symptoms and rash.

An exploratory analysis of pooled data from both trials revealed that treatment with pirfenidone resulted in a 30% relative reduction in the percentage of patients who experienced an absolute decline in percent predicted FVC of at least 10%. This magnitude of decline is considered clinically meaningful as a decline in percent predicted FVC as small as 5% over a six-month period has been shown to be an independent predictor of mortality in patients with IPF, as reported in the du Bois presentation at ATS.

InterMune expects to submit a new drug application (NDA) to the FDA in the summer of 2009 and a marketing authorization application (MAA) to the European authorities around the end of 2009.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease that affects a total of approximately 200,000 people in the United States and Europe, with approximately 30,000 new cases developing in the United States alone, each year. There are no medicines approved by the U.S. Food and Drug Administration (FDA) or European Medicines Evaluation Agency (EMEA) for the treatment of IPF. On October 16, 2008, pirfenidone was approved for marketing in Japan as Pirespa(R), the first regulatory approval of any treatment for IPF in any major market in the world. IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough. IPF is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years.

About Pirfenidone

Prior in-vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreas
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. CMSA Delivers Important Message to Congress: Case Management Services Improve Patient Care and Should Be Key Strategy in Health Care Reform Initiatives
2. What Motivates Physicians to Succeed? Money Isn't Most Important
3. Major statin study reveals several important findings for reducing prostate cancer and disease
4. Leapfrog Group Hospital Survey Finds Majority of Hospitals Fail to Meet Important Quality Standards
5. New Research Shows Tree Nuts May Play an Important Role in the Health of People With Diabetes
6. UT Southwestern researchers reveal how the brain processes important information
7. Nu Skin Charitable Promotion Reaches Important Milestone: 100,000 Trees Donated to African Nation of Malawi
8. AUDIO from Medialink and Mens Health Network: Important Decision Regarding Prostate Cancer
9. Penn researchers identify new protein important in breast cancer genes role in DNA repair
10. Important new model shows how proteins find the right DNA sequences
11. Why Blood and Bone Marrow Donors Are So Important: Extreme Makeover: Home Edition Profiles Blood Drive Honoree Lizzie Bell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... News: 2015-2016 Oil Market Forecast, Company: ... http://www.carsonenergy.com , In July, 2014, the price ... boom in US shale production and increased production from ... market share from US shale producers, started producing close ... oil out into the marketplace, they could push oil ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 Wimbledon ... provides vascular, electrocardiogram (EKG), echocardiogram and NCV testing, ... most recent guidelines for EKG interpretation of athletes. ... leading cause of death during athletic activity. New findings ... the continued discussion to improve cardiac safety in athletes. ...
(Date:5/29/2015)... Astoria, NY (PRWEB) May 29, 2015 Thursday, ... United States. People from all walks of life came ... , Because Red Nose Day is a campaign dedicated to ... by simply having fun and making people laugh, the people ... their clinic in Astoria. Here they provided food, fun ...
(Date:5/29/2015)... Houston, TX (PRWEB) May 29, 2015 ... lorcaserin, is an FDA approved prescription diet medication. ... treatment of obesity when individuals have a BMI >30. ... BMI >27 with at least one additional weight-related health ... cholesterol. , Belviq’s main function for weight ...
(Date:5/28/2015)... May 28, 2015 External Counterpulsation (EECP/ECP) ... all over the United States. There are a growing ... who can experience symptoms of angina and these patients ... stents and/or bypass surgery. , “No option” patients are ... coronary artery disease that is considered unacceptable for heart ...
Breaking Medicine News(10 mins):Health News:Breaking News: Carson Energy Releases 2015-2016 Oil Forecast 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2
... ALEXANDRIA, Va., March 26 The following is,an op-ed ... Community,Pharmacists Association:, With a renewed national spotlight on ... note as well the often,over-looked issue of crimes against ... powerful pain killers and other controlled,substances is a federal ...
... March 26 Golub Capital today announced ... debt financing (through Golub,Capital,s proprietary GOLD facility) ... market leader providing precision tubing solutions to ... in Placentia, Calif.,ExtruMed,s products are used in ...
... to reinvent excellence in global,healthcare delivery, WASHINGTON, ... Tatweer, the world,s first integrated healthcare free zone,announced ... Officer of,their recently launched University Hospital. The University ... of life sciences research, post,graduate medical education, and ...
... Technologies, Inc.,which is developing innovative, patient-friendly medical ... Obstructive Pulmonary Disease,(COPD), cystic fibrosis, and influenza ... million in its second round of venture ... Caufield & Byers (KPCB) with participation from,existing ...
... among pet owners, JEFFERSONVILLE, Ind., March 26 ... your usual route through the park...,and only after seeing ... of broken glass a few steps behind. What do ... respond to an emergency with,their pet. Each year in ...
... Sun Exposure in Light of New Evidence Showing ... WASHINGTON, March 26 Today, the Indoor,Tanning Association ... to rethink sun-tanning and criticizing,dermatologists and the sunscreen ... sun., The advertising blitz begins with a ...
Cached Medicine News:Health News:Independent Pharmacies Protecting You and Your Medications 2Health News:Golub Capital Provides $29.5 Million GOLD Facility in Support of the Recapitalization of ExtruMed 2Health News:Dubai Healthcare City Announces Appointment of James Kingsbury as Chief Executive Officer of University Hospital 2Health News:Dubai Healthcare City Announces Appointment of James Kingsbury as Chief Executive Officer of University Hospital 3Health News:Dubai Healthcare City Announces Appointment of James Kingsbury as Chief Executive Officer of University Hospital 4Health News:Dubai Healthcare City Announces Appointment of James Kingsbury as Chief Executive Officer of University Hospital 5Health News:Breathe Technologies, Inc. Closes on $15 Million in Venture Funding Led by Kleiner Perkins Caufield & Byers 2Health News:Pets Benefit from First Aid Too 2Health News:Indoor Tanning Association Launches Campaign Attacking Melanoma Hype 2
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/29/2015)... 2015  World-renowned prostate surgeon and New York Urologist, Dr. ... of MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive ... Center at Lenox Hill Hospital is the only center ... New York City . We,ve seen tremendous improvement ... The use of an MRI makes for a much more ...
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company ... its previously announced cash tender offer for up to $1.6 ... securities. Holders of notes who tendered, and did ... New York City time, on May ... for purchase by Lilly, are eligible to receive the total ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... Inc. has initiated Phase I/II clinical studies with ... Phase I/II safety and tolerability study in 18 ... cancer has begun,enrolment in the US. Secondary objectives ... vaccine to induce prostate antigen-specific immune,responses, as well ...
... of Clinical Oncology meeting indicate ... data., PRINCETON, N.J., June 3 Celator ... clinical trial in patients,with advanced colorectal cancer. CPX-1 ... on the company,s proprietary,CombiPlex(TM) technology. The results were ...
Cached Medicine Technology:BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
... Complete MoisturePlus is ... multi-purpose solution to offer ... essential electrolytes and taurine. ... protein, stores and conditions ...
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Light weight adjustable trial frame - Child...
Half Trial Frames with precision engineering and lightweight material....
Medicine Products: